2018
SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis
Zhou HJ, Xu Z, Wang Z, Zhang H, Zhuang Z, Simons M, Min W. SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. Nature Communications 2018, 9: 3303. PMID: 30120232, PMCID: PMC6098000, DOI: 10.1038/s41467-018-05812-2.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCorneaCysteine EndopeptidasesDiabetes MellitusEndopeptidasesGene DeletionGene Knock-In TechniquesGene SilencingGolgi ApparatusHuman Umbilical Vein Endothelial CellsHumansIntracellular SpaceMaleMice, Inbred C57BLMice, KnockoutNeovascularization, PathologicProtein TransportRetinaSignal TransductionSUMO-1 ProteinSumoylationVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2ConceptsPathological angiogenesisPotential therapeutic targetRegulation of VEGFR2Non-sumoylated formEndothelial-specific deletionDiabetic miceHindlimb ischemiaTherapeutic targetDiabetic settingControl of angiogenesisEndothelial cellsAngiogenesisVEGFR2Surface expressionVEGFR2 activityTissue repairSENP1
2003
Angiogenesis Therapies for Coronary Artery Disease
Simons M. Angiogenesis Therapies for Coronary Artery Disease. Methods In Pharmacology And Toxicology 2003, 0: 407-419. DOI: 10.1385/1-59259-404-2:407.Peer-Reviewed Original Research
2001
GENE TRANSFER FOR ANGIOGENESIS IN CORONARY ARTERY DISEASE
Laham R, Simons M, Sellke F. GENE TRANSFER FOR ANGIOGENESIS IN CORONARY ARTERY DISEASE. Annual Review Of Medicine 2001, 52: 485-502. PMID: 11160791, DOI: 10.1146/annurev.med.52.1.485.Peer-Reviewed Original ResearchConceptsPromising novel therapeutic strategyAvailable preclinical dataStandard revascularization strategyPeripheral vascular diseaseCoronary artery diseasePreliminary clinical experienceNovel therapeutic strategiesCell-based vectorsRevascularization strategyArtery diseasePreclinical dataVascular diseaseClinical trialsIschemic heartBlood flowTherapeutic strategiesClinical experienceTherapeutic angiogenesisAngiogenesisDelivery modalitiesGene transfer studiesDiseaseGene transfer vectorsPreliminary naturePatients
2000
Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery.
Laham R, Post M, Sellke F, Simons M. Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Current Interventional Cardiology Reports 2000, 2: 213-217. PMID: 11096670.Peer-Reviewed Original ResearchIschemic heart diseaseTherapeutic angiogenesisHeart diseaseCoronary artery bypass surgeryPericardial deliveryPotential new treatment strategyLocal perivascular deliveryArtery bypass surgeryNew treatment strategiesGrowth factor-induced angiogenesisClinical therapeutic angiogenesisNew blood vesselsBypass surgeryPerivascular deliveryIschemic myocardiumEpicardial vesselsTreatment strategiesAngiogenic cytokinesTheoretic advantagesSustained exposureBlood vesselsAngiogenesisDelivery modalitiesLimited dataPoor understandingTherapeutic Angiogenesis
Simons M, Laham R, Post M, Sellke F. Therapeutic Angiogenesis. BioDrugs 2000, 14: 13-20. PMID: 18034552, DOI: 10.2165/00063030-200014010-00002.Peer-Reviewed Original ResearchGrowth factorTherapeutic angiogenesisAdvanced coronary diseaseAdverse effect profileInitial clinical dataRecent clinical experienceBasic fibroblast growth factorQuality of lifeAngiogenic growth factorsFibroblast growth factorCoronary diseaseEffect profileClinical dataPreclinical studiesAnimal modelsClinical experienceNew vasculatureClinical applicationPractical clinical applicationsAngiogenesisBFGFBasic biologyPatientsFactorsSymptomsPR39, a peptide regulator of angiogenesis
Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg R, Hampton T, Li J, Sellke F, Carmeliet P, Simons M. PR39, a peptide regulator of angiogenesis. Nature Medicine 2000, 6: 49-55. PMID: 10613823, DOI: 10.1038/71527.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntimicrobial Cationic PeptidesAortaCapillariesCattleCell HypoxiaCells, CulturedCoronary VesselsCysteine EndopeptidasesDNA-Binding ProteinsEndothelium, VascularHeartHumansHypoxia-Inducible Factor 1Hypoxia-Inducible Factor 1, alpha SubunitIn Vitro TechniquesMacrophagesMiceMice, Inbred C57BLMice, TransgenicMultienzyme ComplexesMyocardial InfarctionMyocardial IschemiaNeovascularization, PhysiologicNuclear ProteinsPeptidesProteasome Endopeptidase ComplexRecombinant ProteinsSwineTranscription FactorsUbiquitinsUmbilical VeinsVon Willebrand FactorConceptsHypoxia-inducible factor-1α (HIF-1α) degradationMacrophage-derived peptideHypoxia-inducible factor-1α (HIF-1α) proteinCoronary flow studiesInflammation-induced angiogenesisInduction of angiogenesisMyocardial vasculatureTissue injuryPotent inductorFunctional blood vesselsBlood vesselsVascular structuresAngiogenesisSelective inhibitionPR39
1999
Angiogenesis in Cardiovascular Disease
Sellke F, Simons M. Angiogenesis in Cardiovascular Disease. Drugs 1999, 58: 391-396. PMID: 10493268, DOI: 10.2165/00003495-199958030-00001.Peer-Reviewed Original ResearchConceptsInoperable coronary artery diseaseTherapeutic angiogenesisChronic myocardial ischaemiaCoronary artery diseasePreliminary clinical trialsAngiogenic growth factorsMyocardial revascularisationArtery diseaseMyocardial ischaemiaTreatment optionsGrowth factor proteinClinical trialsCardiovascular diseaseMyocardial perfusionProtein administrationAnimal modelsAngiogenic factorsObjective evidenceGrowth factorAngiogenesisPatientsDiseaseAdministrationGene therapyOptimal candidatesTherapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery
Laham R, Simons M, Hung D. Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clinical Cardiology 1999, 22: 6-9. PMID: 9929761, PMCID: PMC6655779, DOI: 10.1002/clc.4960221305.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCoronary CirculationCoronary VesselsDisease Models, AnimalEndothelial Growth FactorsFibroblast Growth Factor 1Fibroblast Growth Factor 2InjectionsLymphokinesMyocardial IschemiaNeovascularization, PhysiologicPericardiumReproducibility of ResultsSafetyVascular Endothelial Growth Factor AVascular Endothelial Growth Factors